NEW COMBINATION: SARCLISA + Kyprolis® (carfilzomib) and dexamethasone
Learn moreGoing progression free longer means going longer without your Multiple Myeloma getting worse
In a clinical study, SARCLISA given with Pomalyst® (pomalidomide) and dexamethasone (Pd) extended the time people lived without their multiple myeloma getting worse compared to Pd alone (median of 11.5 months vs 6.5 months).
SARCLISA was
proven in a Phase 3 study.
SARCLISA is a targeted
immunotherapy that works
together with your
immune system.
CareASSIST helps eligible patients with access and support for SARCLISA.
SARCLISA Stories
Hear stories from people who are living with relapsed refractory Multiple Myeloma or caring for someone who is.